diphenylamine has been researched along with tamoxifen in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Collins, MJ; Harrisingh, MC; Kerai, AP; Lloyd, AC; Napoli, I; Noon, LA; Parrinello, S; Ribeiro, S; Rosenberg, LH; White, IJ; Woodhoo, A | 1 |
| Fujita, A; Funakami, Y; Ichida, S; Imano, M; Itoh, T; Nishida, S; Ogawa, N; Sakamoto, K; Satou, T; Shimaoka, H; Suzuyama, N; Takeda, T; Tani, T; Tsubaki, M | 1 |
| Hazenoot, M; Jansen, MPHM; Kockx, CEM; Koedoot, E; Martens, JWM; Meerman, JHN; Pont, C; Timmermans, AM; van de Water, B; van IJcken, WFJ; Venneker, S; Wester, L; Zhang, Y | 1 |
3 other study(ies) available for diphenylamine and tamoxifen
| Article | Year |
|---|---|
A central role for the ERK-signaling pathway in controlling Schwann cell plasticity and peripheral nerve regeneration in vivo.
Topics: Animals; Animals, Newborn; Benzamides; Cell Movement; Cyclin D1; Cytokines; Diphenylamine; Estrogen Antagonists; Gene Expression Regulation; Leukocytes; Male; MAP Kinase Signaling System; Mast Cells; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microscopy, Confocal; Microscopy, Electron, Transmission; Microscopy, Immunoelectron; Motor Activity; Myelin Sheath; Nerve Regeneration; Neutrophils; Peripheral Nerve Injuries; Proto-Oncogene Proteins c-raf; Reaction Time; Receptor, Nerve Growth Factor; Receptors, Estrogen; Recovery of Function; Schwann Cells; T-Lymphocytes; Tamoxifen; Time Factors | 2012 |
PKC/MEK inhibitors suppress oxaliplatin-induced neuropathy and potentiate the antitumor effects.
Topics: Animals; Benzamides; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Diphenylamine; Disease Models, Animal; Drug Synergism; Hyperalgesia; Male; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Organoplatinum Compounds; Oxaliplatin; Protein Kinase Inhibitors; Spinal Cord; Tamoxifen | 2015 |
A kinase inhibitor screen reveals MEK1/2 as a novel therapeutic target to antagonize IGF1R-mediated antiestrogen resistance in ERĪ±-positive luminal breast cancer.
Topics: Anaplastic Lymphoma Kinase; Benzamides; Breast Neoplasms; Cell Line, Tumor; Diphenylamine; Drug Resistance, Neoplasm; ErbB Receptors; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor Modulators; Female; Humans; Insulin-Like Growth Factor I; Mitogen-Activated Protein Kinase Kinases; Protein Kinase Inhibitors; Receptor, IGF Type 1; Tamoxifen | 2022 |